The point at which lung cancer is diagnosed plays a key role in treatment and survival. The average 5-year survival rate for lung cancer diagnosed while still localized (stage I) is 61%.
Participating in a clinical trial gives patients the ability to try the newest treatments that otherwise are not available. There are many ongoing clinical trials testing new lung cancer treatments, including targeted therapies, chemotherapy, radiation therapy, and immunotherapy, alone and in combination.
Each year, there is one key conference dedicated to bringing stakeholders together with the sole goal of discussing the development of treatments for thoracic cancer — the Targeted Therapies of Lung Cancer Meeting.
A diagnosis of cancer has an impact on the entire family. Emotional support from family and friends can make a significant difference to the experience of survivorship, but knowing when, how, and in what way to offer support can be a challenge to figure out.
Paul K. Paik, MD, medical oncologist and researcher at Memorial Sloan Kettering Cancer Center and a member of LUNGevity’s Scientific Advisory Board, sat down to talk about what squamous cell lung cancer is and where we stand with treatment options for this disease.
Communication is critical to a positive doctor-patient relationship. Knowing the right questions to ask helps ensure you leave your appointments with the information and answers you need. Being prepared may also lessen anxiety and help provide a sense of control.
